<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Major changes have occurred in the transplantation of hematopoietic stem cells (<z:chebi fb="15" ids="50443">HSCs</z:chebi>) during the last decade </plain></SENT>
<SENT sid="1" pm="."><plain>This report reveals the changes, reflects current status, and provides medium-term projections of <z:chebi fb="15" ids="50443">HSC</z:chebi> transplantation (HSCT) development in Europe </plain></SENT>
<SENT sid="2" pm="."><plain>Data on 132 963 patients, 44 165 with allogeneic <z:chebi fb="15" ids="50443">HSC</z:chebi> transplant (33%) and 88 798 with an autologous <z:chebi fb="15" ids="50443">HSC</z:chebi> transplant (67%), collected prospectively from 619 centers by the European Group for Blood and Marrow Transplantation (EBMT) in 35 European countries between 1990 (4234 HSCTs) and 2000 (19 136 HSCTs) illustrate utilization of HSCT </plain></SENT>
<SENT sid="3" pm="."><plain>HSCT increased in <z:hpo ids='HP_0000001'>all</z:hpo> European countries and for <z:hpo ids='HP_0000001'>all</z:hpo> indications </plain></SENT>
<SENT sid="4" pm="."><plain>There were major differences depending on disease indication and donor type </plain></SENT>
<SENT sid="5" pm="."><plain>Transplantation rates (numbers of HSCTs per 10 million inhabitants) varied from less than 1 for some rare indications to 37.7 +/- 4.1 for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> in allogeneic HSCT or 95.5 +/- 13.5 for non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in autologous HSCT </plain></SENT>
<SENT sid="6" pm="."><plain>There were indications with a steady, continuing increase and others with initial increase but subsequent decrease </plain></SENT>
<SENT sid="7" pm="."><plain>Projections on medium-term development for each disease based on a weighted sensitivity analysis predict an ongoing increase in allogeneic HSCT except for <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In autologous HSCT they predict an increase for <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and some <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> but a decrease for most <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo>, and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Transplantation rates can be predicted with reasonable sensitivity for most disease indications </plain></SENT>
<SENT sid="10" pm="."><plain>Despite marked changes in the rapidly developing field of HSCT, this information on current use, trends, and midterm predictions forms a rational basis for patient counseling and health care planning </plain></SENT>
</text></document>